Breast cancer is often hormone responsive, since growth or regression of tumors can often
be modulated by appropriate endocrine manipulations. Estrogen and progesterone appear …

Estrogen receptor protein is known to be an important prognostic factor for patients with
breast cancer. The presence of estrogen receptor correlates with response to endocrine …

The estrogen receptor (ER) assay has become a standard practice in the management of
advanced breast cancer. Tumors lacking ER respond infrequently to endocrine therapy …

The measurement of cytoplasmic estrogen receptor in tumors from patients with breast
cancer is now well established. Potential uses include prognosis of early recurrence …

Our present state of knowledge regarding estrogen and progesterone receptors (ER and
PgR) has led to changes in. treatment strategies: patients without receptors in their tumor …

The synthetic progestin, R5020, has been used to demonstrate a progesterone receptor
(PGR) in 7, 12-dimethylbenz (α) anthracene-induced rat mammary tumors which binds …

The identification of steroid receptors in human breast cancer tissues has provided
biochemical markers to predict hormone responsiveness. Analysis of tumors from 328 …

An obvious problem for the surgeon or oncologist treating breast cancer has been to identify
the patients likely to respond to endocrine manipulation. Until recently, clinical factors such …

The presence of progesterone receptors was found to be associated with a favorable
prognosis in 98 patients with primary breast cancer. The occurrence of metastases was 3.6 …

Abstract From October 1977 to December 1983, estrogen receptor (ER) and progesterone
receptor (PR) levels were measured in 645 tumors from women with primary, unilateral …